HOME >> BIOLOGY >> NEWS
Targeted genetics presents promising data from cystic fibrosis clinical trial

Studies suggest that aerosolized tgAAV-CF is safe, well tolerated, and efficiently delivered to the lung

Seattle, WA-June 5, 2000-Targeted Genetics Corporation (Nasdaq: TGEN) presented data from its Phase I clinical trial of an aerosol formulation of tgAAV-CF, the Company's gene therapy product for the treatment of cystic fibrosis (CF). Dr. Thomas C. Reynolds, Vice President, Clinical Affairs at Targeted Genetics, presented the data in an abstract titled "A Phase I Study of Aerosolized Administration of tgAAV-CF to CF patients with Mild Lung Disease" this weekend at the American Society of Gene Therapy Third Annual Meeting in Denver, Colorado.

The Phase I dose-escalation study evaluated the safety and tolerability of tgAAV-CF delivered via nebulizer to 12 patients age 19-41 (median age 29) with mild CF lung disease. All patients in the study had FEV1 levels (a standard measure of lung function) at least 60% of normal. Doses of 1010, 1011, 1012 and 1013 DNAse Resistant Particles (DRP) were evaluated, with each cohort containing three patients. Patients received a single dose of tgAAV-CF and were followed for 90 days post treatment.

"The aerosolized formulation of tgAAV-CF, which we are developing in collaboration with Celltech Group, plc, is well-tolerated in this patient population," said Dr. Reynolds. "Our ability to achieve broad distribution of tgAAV-CF throughout the lungs of these patients validates the aerosol delivery approach we are taking in developing this product. We are on track to initiate a Phase II multi-dose study of aerosolized tgAAV-CF within the next several months. As with the Phase I study presented today, we are working closely with the Cystic Fibrosis Foundation's Therapeutics Development Network (CFF TDN) in designing and conducting the Phase II study. tgAAV-CF is the first gene therapy approach for CF to be selected by the TDN for collaboration and we are proud to be working with the leading physicians
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 ext 229
Noonan/Russo Communications
4-Jun-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... has dedicated his career to understanding the Earth,s ... audience. , As deputy director and regional climatologist ... Desert Research Institute, Redmond has more than three ... dissemination of climate data to the general public. ... San Francisco on December 15-19, 2014 the American ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
(Date:11/21/2014)... (PRWEB) November 20, 2014 ... (XNA, Chassis, Oligos, Enzymes, Cloning kits), Technology ... Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global ... major market drivers, threats, opportunities, and challenges. ... 46 figures spread through 185 pages and ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... and SAN DIEGO , Nov. 20, 2014 ... President and CEO Marc Hedrick , M.D. will present ...   Thursday, December 4, 2014 TIME:    11:15 am ... or paste this URL into your browser,s address bar: ... pre-register to save time and receive event updates. ...
(Date:11/18/2014)... 17, 2014 Cirrascale Corporation ... blade-based and rackmount computing infrastructure, today announced it ... accelerator throughout its GPU-enabled blade server and high-performance ... company’s latest proprietary 80-lane Gen3 PCIe switch-enabled risers, ... Tesla K80 dual-GPU accelerator cards in a single ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
Cached News: